Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period

2:00 PM - 2:45 PM (EST), Monday, February 6, 2023 ・ South Broadway Ballroom

Atlas Venture reports in its 2022 Year in Review, there are "7000 drugs in clinical development around the world, supported by $200B of R&D spend".  With R&D being the lifeline of many biopharma companies, companies are feeling the pressure to get more done with capital already raised against a backdrop of a volatile economic environment and uncertain capital market.  What strategies are companies deploying to keep foundational R&D progressing?  How are executive teams managing CROs?  Are there opportunities for CROs to demonstrate better alignment with the rising costs and a tougher funding environment challenging biopharma companies?  

Moderator
photo
Americas Industry Market Leader for Life Sciences and Healthcare
Ernst & Young LLP
Speakers
photo
CEO & Co-Founder
Vial
photo
CEO
Syneos Health
photo
Advisor and Founder, Clinical Innovations Partners; Co-Chair
DTRA
photo
Chief Executive Officer
Paratek Pharmaceuticals, Inc
photo
Americas Industry Market Leader for Life Sciences and Healthcare
Ernst & Young LLP